AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01189201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin SID
Description: medium single dose of mono components BI 10773/linagliptin
Study NCT01189201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin FDC
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
Study NCT01379339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 10mg/m2
Description: * Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study NCT01379339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 12.5mg/m2
Description: * Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study NCT01379339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 15mg/m2
Description: * Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study NCT01379339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 17.5mg/m2
Description: * Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study NCT01379339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20mg/m2
Description: * Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study NCT00204568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: 60 mg/m2, d1, W d22
Study NCT02355210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose powder, 5 grams
Study NCT00204568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trofosfamide
Description: 300 mg absolute d1-7, followed by 150 mg absolute continuously
Study NCT04676581 — intervention group
Intervention type: OTHER
Intervention: Leech Therapy
Description: Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Visit Survey
Description: In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Visit Survey
Description: In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up Questionnaire
Description: 12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Questionnaire
Description: 12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
Study NCT01154231 — intervention group
Intervention type: DRUG
Intervention: Nonacog Alfa (Genetical Recombination)
Description: Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less.
Study NCT04348201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: foot reflexology
Description: foot reflexology session which takes about 20 minutes. The position of the patient during reflexology session was a relaxed comfortable supine lying position. The therapist was sitting position at the level of the feet. The Session of reflexology was done on three points at both feet.
Study NCT04348201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary modification
Description: diet must be rich in vitamins as fish and beans, calcium as milk and chess, low fat food through decrease oil in meals, high fiber food through all types of vegetables and fruits and restrict caffeine
Study NCT02711163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed formula
Study NCT02711163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid formula
Study NCT03295955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanate
Description: Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery
Study NCT00524940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, Split-Virion Influenza Virus
Description: 0.5 mL, Intramuscular
Study NCT02109809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total nodal irradiation
Description: Undergo TLI
Study NCT01034878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
Study NCT00631592 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1349572
Study NCT02109809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02109809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03799432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COAST-IS
Description: COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.
Study NCT03799432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT Learning Collaborative
Description: The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
Study NCT00704860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open label pharmacotherapy
Description: Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,
Study NCT02606058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred cord clamping
Description: Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
Study NCT03691662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Ophthalmic Solution
Description: Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
Study NCT03799432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TF-CBT Learning Collaborative
Description: The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
Study NCT03073824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vSculpt
Description: Pelvic Floor Toning and Vaginal Rejuvenation Device
Study NCT01508884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
Study NCT01508884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: pretreatment with topical imiquimod cream to the injection site before vaccination
Study NCT01508884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
Study NCT01508884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream
Description: pretreatment with topical aqueous cream to the injection site before vaccination
Study NCT01508884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
Study NCT04468685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Interperitoneal administration in the gall bladder bed
Study NCT04468685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Interperitoneal administration in the gall bladder bed
Study NCT03691662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5%
Description: Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
Study NCT03338530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive School-Based Intervention
Description: School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
Study NCT00491868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
Study NCT00491868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
Study NCT00491868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: 2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
Study NCT03416452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibratory cueing device
Description: ankle brace with vibrator that provides electric stimulus
Study NCT03416452 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mobile Gait Trainer
Description: standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
Study NCT03416452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Gait Trainer
Description: standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
Study NCT00491868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: 4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
Study NCT00491868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R744 placebo
Description: 0 μg/4week for 24 weeks
Study NCT00491868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuEPO placebo
Description: 0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks
Study NCT02254265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-101 0.05%
Description: OTX-101 0.05% Ophthalmic Solution
Study NCT02254265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Description: OTX-101 0.09% Ophthalmic Solution
Study NCT02254265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of OTX-101 Ophthalmic Solution
Study NCT04553393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be added 1 month after responding to CART cells infusion
Study NCT04553393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be added 1 month after responding to CART cells infusion
Study NCT04553393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide and Decitabine
Description: Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
Study NCT04553393 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine-primed Tandem CAR19/20 engineered T cells
Description: Tandem CAR19/20 engineered T cells
Study NCT00573352 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared
Description: Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
Study NCT04553393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decitabine-primed Tandem CAR19/20 engineered T cells
Description: Tandem CAR19/20 engineered T cells
Study NCT03514095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Stimulation Therapy Program
Description: This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program.
Study NCT04784611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention
Description: Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
Study NCT00641017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine
Description: Live attenuated Human Parainfluenza Type 1 Virus Vaccine
Study NCT00635310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous liver biopsy
Description: Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
Study NCT00716391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TPF, radiotherapy and cisplatin.
Description: 3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
Study NCT00716391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPF, radiotherapy and cetuximab.
Description: 3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
Study NCT01849237 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).
Study NCT01849237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy of septic shock
Description: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Study NCT01849237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy of septic shock
Description: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
Study NCT04940988 — intervention group
Intervention type: OTHER
Intervention: Real-time benefits check
Description: Prescribers practicing in outpatient departments assigned to the intervention arm will be shown popup alerts with their patient's insurance benefit design-specific out-of-pocket cost for the drug being ordered as well as out-of-pocket costs for up to 3 lower-cost alternatives if available. Alternatives will only be shown when available and when the patient and his or her benefit design information can be matched by the electronic health record system to accurately query out-of-pocket cost information.